321 views, By Xi'an OriginBio Technology Co., Ltd.
OriginBio has published a technical guide examining the role of liposomal delivery in functional nutrition. The guide explains how phospholipid vesicles are designed, processed and evaluated for use in supplement formulation.
A3 Analytics, the AI-native operational intelligence company for automated and self-driving laboratories, today announced that Greg Snyder, PhD, has joined the company as Co-Founder and Chief Operating Officer.
With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's..
SignaBlok, Inc. has been awarded a Phase I SBIR grant from the NIH NIDDK to advance the development of a novel mechanism-based therapy for inflammatory bowel disease (IBD). The award supports SignaBlok's differentiated approach to targeting TREM-1 in IBD.
With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts
Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to...
NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...
Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.
Nomination recognizes synseer's mission to transform the ear into a continuous health-intelligence platform helping people understand, manage and extend their healthspan.
First-cycle FDA review delivers one of the strongest signals yet that NRx's preservative-free ketamine opportunity may be entering its final stretch, while the company's broader neuropsychiatric pipeline continues to gain momentum.
Boston Industrial Solutions announces the launch of SAP-G70 Silicone Primer, designed for effective bonding of silicone to silicone and various other materials.
Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Natural Field, a nutraceutical ingredient manufacturer specializing in innovative delivery systems, unveiled NF TriSolve® at CPHI China 2026, showcasing its latest advancement in science-driven nutritional formulation solutions.
As Southern Nevada public systems face mounting pressure, families seeking timely answers after the death of a loved one are often left waiting in uncertainty.
A growing number of families in Phoenix and across Arizona are seeking independent medical examinations through private autopsy services to find definitive answers following the loss of a loved one.
Independent analysis puts Base fair value near $63 per share against a $104.71 reference price, with 6,000 prevalent patient starts reaching only ~$91.
321 views, By Xi'an OriginBio Technology Co., Ltd.
OriginBio has published a technical guide examining the role of liposomal delivery in functional nutrition. The guide explains how phospholipid vesicles are designed, processed and evaluated for use in supplement formulation.
A3 Analytics, the AI-native operational intelligence company for automated and self-driving laboratories, today announced that Greg Snyder, PhD, has joined the company as Co-Founder and Chief Operating Officer.
With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's..
Artificial Organs Market is projected to expand from USD 28.71 billion in 2025 to USD 63.31 billion by 2035, driven by rising organ failure, implantable technologies, advanced biomaterials, bioengineering and 3D bioprinting.
SignaBlok, Inc. has been awarded a Phase I SBIR grant from the NIH NIDDK to advance the development of a novel mechanism-based therapy for inflammatory bowel disease (IBD). The award supports SignaBlok's differentiated approach to targeting TREM-1 in IBD.
With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts
Dr.Pati Abhay Kumar USA Profile : https://www.Patikumar.com Real Story of Ayurveda & AYURVEDIC SCIENCE & Medicine Medicine means art of healing Medicine does not mean Emergency Chemically synthesized pharma drug at all.
Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to...
Independent simulation estimates ~19% probability of null Lp(a) biology and reduces OCEAN(a)'s modeled statistical-success probability from 87.9% to ~65–72%
NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...
Neurogut Inc. is proud to announce the granting of US Patent US12575788B2 for its Bioanatoner device, a groundbreaking biofeedback system designed to transform the treatment of anorectal and pelvic floor disorders.
Independent analysis finds Zenkuda more likely than not to achieve non-inferiority, while the quality of vision preservation and achieved dosing durability could produce materially different commercial and valuation outcomes.
MARKET OVERVIEW: Precision fermentation is moving beyond alternative dairy into collagen, nutraceuticals, functional nutrition and specialty ingredients.
Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.
Metavalis Inc. details advanced R&D across genomic radioprotection, neural interfacing, and cryopreservation, powered by the A.L.I.C.E. computational platform.
Nomination recognizes synseer's mission to transform the ear into a continuous health-intelligence platform helping people understand, manage and extend their healthspan.
Independent analysis finds ulixacaltamide approval increasingly likely, while identifying residual FDA uncertainty and post-approval commercial persistence as underappreciated risks.
The strategic capital injection will scale biological payloads and expand the V18 Prometheus neural topology of the world's most powerful AI, A.L.I.C.E.
First-cycle FDA review delivers one of the strongest signals yet that NRx's preservative-free ketamine opportunity may be entering its final stretch, while the company's broader neuropsychiatric pipeline continues to gain momentum.
Boston Industrial Solutions announces the launch of SAP-G70 Silicone Primer, designed for effective bonding of silicone to silicone and various other materials.
